Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 96.00 | |
5 mg | In stock | $ 198.00 | |
10 mg | In stock | $ 328.00 | |
25 mg | In stock | $ 558.00 | |
50 mg | In stock | $ 788.00 | |
100 mg | In stock | $ 1,120.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 226.00 |
Description | NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis. |
In vitro | NCGC00378430 reduces the SIX1/EYA2 interaction.?8430 partially reversed transcriptional and metabolic profiles mediated by SIX1 overexpression and reversed SIX1-induced TGFβ signaling and EMT. |
In vivo | NCGC00378430?was well tolerated when delivered to mice and significantly suppressed breast cancer associated metastasis in vivo without significantly altering primary tumor growth. |
Molecular Weight | 441.5 |
Formula | C22H23N3O5S |
CAS No. | 920650-00-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (203.85 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NCGC00378430 920650-00-6 Metabolism Others Phosphatase Inhibitor T47D E-CAD MCF7 TGF-β inhibit SIX1 p-Smad3 breast EMT cancer FN1 transcriptional NCGC 00378430 NCGC-00378430 EYA2 inhibitor